Author

Raetasha Sheavette Dabney

Observed names: Raetasha Dabney, Raetasha S Dabney, Raetasha S. Dabney

Institution: Texas Oncology

Observed institutions: Brooke Army Medical Center, Texas Oncology, Keesler Medical Center, Center for Cancer and Blood Disorders, The University of Texas Health Science Center at Tyler

OpenAlex ID: A5072220626

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

2022 · Emrullah Yilmaz, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 105

Immunotherapy and targeted therapy—the new roadmap in cancer treatment

2019 · Kamran Shahid, Mustafa Khalife, et al. · Annals of Translational Medicine · 61

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

2023 · Humera Khurshid, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 60

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

2018 · Valérie de Haas, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 51

New agents in renal cell carcinoma

2013 · Raetasha Dabney, Ryan Devine, et al. · Targeted Oncology · 30

Molecular pathways and targeted therapy in cholangiocarcinoma.

2019 · Raetasha S Dabney, Mustapha Khalife, et al. · PubMed · 18

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

2024 · Gregory P. Kalemkerian, Humera Khurshid, et al. · Journal of Clinical Oncology · 16

Intraosseous hibernoma or unusual location of brown fat?

2012 · David T. Lynch, Raetasha S. Dabney, et al. · Journal of Hematopathology · 14

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

2026 · Lisa K. Hicks, Hans J. Messersmith, et al. · Journal of Clinical Oncology · 9

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A

2023 · Emrullah Yilmaz, Nofisat Ismaila, et al. · JCO Oncology Practice · 4

Stereotactic body radiation therapy and immunotherapy.

2019 · Mustapha Khalife, Kamran Shahid, et al. · PubMed · 4

From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines.

2012 · Timothy J Vreeland, Diane F Hale, et al. · Journal of Clinical Oncology · 3

An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.

2012 · Diane F Hale, Sonia A. Perez, et al. · Journal of Clinical Oncology · 3

Abstract LB-130: Immune reconstitution after chemotherapy correlates with increased in vitro immune response in breast cancer patients undergoing peptide vaccine therapy

2012 · Timothy J. Vreeland, Raetasha S. Dabney, et al. · Cancer Research · 1

Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.

2012 · Raetasha Sheavette Dabney, Diane F Hale, et al. · Journal of Clinical Oncology

Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

2012 · Diane F. Hale, Timothy J. Vreeland, et al. · Cancer Research

Works count: 16

Citation count: 379

H-index: 9

I10-index: 8